INMAZEB biosimilars — when can they launch?
INMAZEB (ATOLTIVIMAB) · BLA761169 · REGENERON PHARMACEUTICALS
Where INMAZEB sits in the biosimilar timeline
BPCIA 12-year reference product exclusivity for INMAZEB extends to 2032 (6 years from today). Biosimilars cannot be approved by the FDA before this date. Biosimilar developers begin clinical comparability studies 4-6 years before the cliff.
Under the US Biologics Price Competition and Innovation Act (BPCIA), a reference biologic is protected from biosimilar competition for 12 years from FDA approval (with 4 years of data exclusivity preventing 351(k) submissions). Biosimilars enter via the abbreviated 351(k) pathway, which requires comparability — not exact identity — to the reference product.
Key dates for INMAZEB
| Event | Date | Status |
|---|---|---|
| FDA approval (BLA filed by REGENERON PHARMACEUTICALS) | 2020-10-14 | Past |
| 4-year data exclusivity ends (first biosimilar 351(k) submission permitted) | 2024-10-14 | Past |
| 12-year reference product exclusivity ends (first biosimilar can be marketed) | 2032-10-14 | Future |
Note: composition-of-matter and method-of-use patent expiries (separate from BPCIA exclusivity) may set the actual launch window. See INMAZEB on Drug Landscape for the full patent picture.
Other REGENERON PHARMACEUTICALS biologics
Sources
- FDA Purple Book — biologic license applications + BPCIA exclusivity
- INMAZEB drug profile — full patent estate, indications, clinical trials
- REGENERON PHARMACEUTICALS patent portfolio
Not legal advice. BPCIA exclusivity may interact with composition-of-matter patents and patent term extensions — see the full drug profile for the consolidated picture.
Track INMAZEB biosimilar entry
Daily alerts when BPCIA exclusivity, ref-product patents, or biosimilar applications change. Free 3 watches, Pro 50.